INMOLD AS

Their core work

Inmold A/S is a Danish SME specializing in roll-to-roll (R2R) manufacturing of micro- and nano-structured surfaces, particularly for microfluidic devices and functional foils. They bring industrial-scale production capability to technologies that are typically stuck at lab scale — translating nano-enabled surface designs into commercially viable products using continuous manufacturing processes. Their work spans from anti-counterfeit security packaging to bioanalytical microfluidic devices, with a consistent focus on bridging the gap between prototype and mass production.

What they specialise in

How they've shifted over time

Inmold started in 2014 with a small Phase 1 feasibility study on anti-counterfeit security foils (ACfoil), suggesting their original business was in functional surface coatings and security packaging. By 2015, they pivoted toward bioanalytical applications through R2R Biofluidics, applying their roll-to-roll expertise to micro- and nano-fabrication of diagnostic devices. Their most recent project (NextGenMicrofluidics, 2020-2025) shows a clear maturation — adding concerns around upscaling validation, quality management, regulatory compliance, and time-to-market, signaling a shift from pure manufacturing toward full production-readiness for microfluidic products.

Inmold is moving from being a manufacturing process specialist toward becoming an end-to-end upscaling partner for microfluidic and nano-enabled devices, including quality assurance and regulatory readiness.

How they like to work

Inmold predominantly operates as a participant in larger Innovation Action (IA) consortia, with their sole coordinator role being a small SME Phase 1 feasibility study. With 25 unique partners across 8 countries from just 3 projects, they work in moderately large consortia and appear open to diverse partnerships rather than sticking to a fixed group. This profile suggests a company that provides specialized manufacturing capability within broader R&D teams — they bring the production know-how while others handle design and application development.

Inmold has built a network of 25 consortium partners across 8 countries through just 3 projects, indicating participation in substantial multi-partner Innovation Actions. Their reach across multiple European countries reflects the typical manufacturing-scale-up ecosystem connecting research labs with industrial production.

What sets them apart

Inmold occupies a specific niche that is hard to find: an SME with proven roll-to-roll production capability for micro- and nano-structured devices. While many labs can fabricate microfluidic prototypes, very few companies can scale these to continuous manufacturing — and even fewer are small enough to be accessible consortium partners. Their recent focus on validation, quality management, and regulatory aspects makes them particularly valuable for projects that need to demonstrate a credible path from lab to market.

Highlights from their portfolio

• NextGenMicrofluidics
  Largest funding (EUR 797K), most recent project, and represents their strategic shift toward full production-readiness for nano-enabled microfluidic devices including validation and regulatory compliance.
• R2R Biofluidics
  Pivotal project that moved Inmold from general foil production into the bioanalytical device space, applying R2R imprinting at large scale for diagnostic applications.
• ACfoil
  Their only coordinator role — a Phase 1 SME instrument exploring anti-counterfeit foil, revealing their original business roots in security packaging.